# Neurozen Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurozen

- Industry: Healthcare
- Headquarters: Seoul, South Korea
- Website: www.neurozen.ai
- Total disclosed funding: $2.7M
- Latest round: Series A (Jul 29, 2021)
- Investors on record: 3

## About

Based in Seoul, South Korea, and founded by CEOs Sunny Lee and Kunho Lee in 2015, Neurozen Co. develops AI-powered neuroimaging and genetic solutions for the risk assessment and early detection of Alzheimer’s disease. Risk assessment and early detection are crucial to helping target the disease before irreversible brain damage or mental decline has occurred. Neurozen Co. has an exclusive license to the largest Asian dementia cohort organized by the National Research Center for Dementia (NRCD). The company works with neuroscientists, radiologists, bioinformatics specialists, and dementia experts to develop unique and effective solutions for Alzheimer's disease. In 2021, Neurozen Co. raised KRW 3.1 billion in series A investment.

The company provides detailed genetic analysis for accurate Alzheimer's disease risk assessment through AI-powered neuroimaging and genetic solutions called NeuroXRP Genetic Testing Service and NeuroXgen Alzheimer’s Risk Assessment Service.

## Funding rounds

- Series A, Jul 29, 2021, $2.7M — DT&Investment, Friend Investment Partners, iPlus Center

## Investors

- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series A
- Friend Investment Partners (https://capitalatlas.ai/funds/friend-investment-partners) — Series A
- iPlus Center — Series A